Refined crystal structure of the interleukin-1 receptor antagonist. Presence of a disulfide link and a cis-proline.

Interleukin-1 (IL-1) molecules are cytokines involved in the acute-phase response against infection and injury. Three naturally occurring IL-1 molecules are known, two agonists: IL-1 alpha and IL-1 beta, and one antagonist, the IL-1 receptor antagonist (IL-1ra). Although IL-1 action protects the organism by enhancing the response to pathogens, its overproduction can lead to pathology and has been implicated in disease states that include septic shock, rheumatoid arthritis, graft versus host disease and certain leukemias. The crystal structure of IL-1ra has been solved at 0.21-nm resolution by molecular replacement using the IL-1 beta structure as a search model. The crystals contain two independent IL-1ra molecules which are very similar. IL-1ra has the same fold as IL-1 alpha and IL-1 beta. The fold consists of twelve beta-strands which form a six-stranded beta-barrel, closed on one side by three beta-hairpin loops. Cys69 and Cys116 are linked via a disulfide bond and Pro53 has been built in the cis-conformation. Comparison of the IL-1ra structure with the IL-1 alpha and IL-1 beta structures present in the Protein Data Bank shows that a putative receptor interaction region, involving the N-terminus up to the beginning of strand beta 1 and the loops D and G, is very different in the three IL-1 molecules. Other putative interaction regions, as identified with mutagenesis studies, are structurally conserved and rigid, allowing precise and specific interactions with the IL-1 receptor.

[1]  M. T. Brewer,et al.  Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist , 1990, Nature.

[2]  S. Jobling,et al.  A point mutation uncouples human interleukin-1 beta biological activity and receptor binding. , 1990, The Journal of biological chemistry.

[3]  W. Kabsch,et al.  Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.

[4]  B. Brandhuber,et al.  X-ray structure of interleukin-1 receptor antagonist at 2.0-A resolution. , 1995, The Journal of biological chemistry.

[5]  A. Schmitz,et al.  A mutational analysis of receptor binding sites of interleukin-1β:differences in binding of human interleukin-1β muteins to human and mouse receptors , 1994 .

[6]  L. Rawlinson,et al.  Interleukin 1 induces NF-kappa B through its type I but not its type II receptor in lymphocytes. , 1992, The Journal of biological chemistry.

[7]  A. Goldman,et al.  Structure of an interleukin-1 beta mutant with reduced bioactivity shows multiple subtle changes in conformation that affect protein-protein recognition. , 1993, Biochemistry.

[8]  S. Sprang,et al.  Three-dimensional structure of human basic fibroblast growth factor, a structural homolog of interleukin 1 beta. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist reduces mortality from endotoxin shock , 1990, Nature.

[10]  A. Mantovani,et al.  Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. , 1993, Science.

[11]  W. Benjamin,et al.  Conversion of the interleukin 1 receptor antagonist into an agonist by site-specific mutagenesis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Brick,et al.  Crystal structure of a Kunitz-type trypsin inhibitor from Erythrina caffra seeds. , 1991, Journal of molecular biology.

[13]  C. Dinarello.  Interleukin-1 and interleukin-1 antagonism. , 1991, Blood.

[14]  J. Navaza,et al.  AMoRe: an automated package for molecular replacement , 1994 .

[15]  R. Thompson,et al.  Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. , 1991, Immunology today.

[16]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor , 1990, Nature.

[17]  A. Schmitz,et al.  The structure of murine interleukin-1 beta at 2.8 A resolution. , 1991, Journal of structural biology.

[18]  S. Dower,et al.  Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. , 1990, Science.

[19]  D. Rees,et al.  Three-dimensional structures of acidic and basic fibroblast growth factors. , 1993, Science.

[20]  A study of structural determinants in the interleukin-1 fold. , 1993, Protein engineering.

[21]  J. Robertus,et al.  Structure of ricin B‐chain at 2.5 Å resolution , 1991, Proteins.

[22]  C. J. Dunn,et al.  Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein , 1990, Nature.

[23]  H. Cherwinski,et al.  Expression in Escherichia coli of synthetic human interleukin-1α genes encoding the processed active protein, mutant proteins, and β-galactosidase fusion proteins , 1986 .

[24]  Brian W. Matthews,et al.  Refinement of the structure of human basic fibroblast growth factor at 1.6 Å resolution and analysis of presumed heparin binding sites by selenate substitution , 1993, Protein science : a publication of the Protein Society.

[25]  Barry C. Finzel,et al.  Crystal structure of recombinant human interleukin-1β at 2·0 Å resolution , 1989 .

[26]  M. T. Brewer,et al.  Interleukin 1 receptor antagonist is a member of the interleukin 1 gene family: evolution of a cytokine control mechanism. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Grütter,et al.  Crystallographic refinement of interleukin 1 beta at 2.0 A resolution. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[28]  E Labriola-Tompkins,et al.  Structure-function analysis of human IL-1 alpha: identification of residues required for binding to the human type I IL-1 receptor. , 1993, Protein engineering.

[29]  Y. Satow,et al.  Structure of interleukin 1 alpha at 2.7-A resolution. , 1990, Biochemistry.

[30]  Barry C. Finzel,et al.  The use of an imaging proportional counter in macromolecular crystallography , 1987 .

[31]  P. Kraulis.  A program to produce both detailed and schematic plots of protein structures , 1991 .

[32]  M. Grütter,et al.  Crystal structure of the cytokine interleukin‐1 beta. , 1988, The EMBO journal.

[33]  R. Bone.  A critical evaluation of new agents for the treatment of sepsis. , 1991, JAMA.

[34]  P. Fitzgerald.  MERLOT, an integrated package of computer programs for the determination of crystal structures by molecular replacement , 1988 .

[35]  G. Zurawski,et al.  Identification of key residues in the amino-terminal third of human interleukin-1 alpha. , 1990, The Journal of biological chemistry.

[36]  Axel T. Brunger,et al.  Extension of molecular replacement: a new search strategy based on Patterson correlation refinement , 1990 .

[37]  R. Horuk,et al.  Muteins of human interleukin‐1 that show enhanced bioactivities , 1987, FEBS letters.

[38]  B. Matthews,et al.  Three-dimensional structure of human basic fibroblast growth factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[39]  R M Sweet,et al.  Crystal structure of the complex of porcine trypsin with soybean trypsin inhibitor (Kunitz) at 2.6-A resolution. , 1974, Biochemistry.

[40]  A. Gronenborn,et al.  High-resolution three-dimensional structure of interleukin 1 beta in solution by three- and four-dimensional nuclear magnetic resonance spectroscopy. , 1992, Biochemistry.

[41]  R. Raag,et al.  Functional implications of interleukin‐1β based on the three‐dimensional structure , 1992 .

[42]  Alexey G. Murzin,et al.  β-Trefoil fold: Patterns of structure and sequence in the Kunitz inhibitors interleukins-1β and 1α and fibroblast growth factors , 1992 .

[43]  M. Yamada,et al.  Structure-activity relationships in human interleukin-1 alpha: identification of key residues for expression of biological activities. , 1992, Protein engineering.

[44]  E. Ulrich,et al.  Secondary structure and topology of interleukin-1 receptor antagonist protein determined by heteronuclear three-dimensional NMR spectroscopy. , 1992, Biochemistry.

[45]  Y. Ohmoto,et al.  Site-specific mutagenesis of the human interleukin-1 beta gene: structure-function analysis of the cysteine residues. , 1988, Biochemical and biophysical research communications.

[46]  M. Hatada,et al.  Identification of the discontinuous binding site in human interleukin 1 beta for the type I interleukin 1 receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[47]  B. Henderson,et al.  Therapeutic potential of cytokine manipulation. , 1992, Trends in pharmacological sciences.

[48]  Y. Ohmoto,et al.  Site-specific mutagenesis of the human interleukin-1 beta gene: the role of arginine residue at the N-terminal region. , 1988, Journal of biochemistry.

[49]  V. Luzzati,et al.  Traitement statistique des erreurs dans la determination des structures cristallines , 1952 .

[50]  A. Gronenborn,et al.  N‐terminal‐methionylated interleukin‐1β has reduced receptor‐binding affinity , 1987 .

[51]  H. Starnes,et al.  Preliminary report: effects of interleukin-1 on platelet counts , 1990, The Lancet.

[52]  A. Gronenborn,et al.  Point mutations of human interleukin‐1 with decreased receptor binding affinity , 1986, FEBS letters.

[53]  J. Gauldie,et al.  The acute phase response. , 1994, Immunology today.

[54]  P. Young,et al.  Mapping of neutralizing epitopes and the receptor binding site of human interleukin 1 beta. , 1993, The Journal of biological chemistry.

[55]  W. Saenger,et al.  The three‐dimensional structure of the bifunctional proteinase k/α‐amylase inhibitor from wheat (PKI3) at 2.5 Å resolution , 1991 .

[56]  W. Kabsch.  A solution for the best rotation to relate two sets of vectors , 1976 .

[57]  T. Holak,et al.  Structure of hisactophilin is similar to interleukin-1β and fibroblast growth factor , 1994, Nature.

[58]  B. Matthews.  Solvent content of protein crystals. , 1968, Journal of molecular biology.